ASCO and ESMO Abstracts 2020

 

ASCO Abstracts

ASCO: Lisocabtagene maraleucel (liso-cel)

Abstract No : 8040

Indication : Non-Hodgkin's Lymphoma (aggressive)

Intervention : Lisocabtagene maraleucel

Company : Juno Therapeutics, a Bristol-Myers Squibb company

Technology : CAR T Cell therapy

These interim data suggest that elderly and/or comorbid pts with R/R aggressive large B-cell NHL, who are not eligible for high-dose chemotherapy and HSCT, can receive 2L liso-cel with similar safety and efficacy to 3L+ pts as previously reported (Abramson, ASH 2019 #241). Updated data with longer follow-up will be presented.

Read More: https://www.delveinsight.com/asco-conference/article/lisocabtagene-maraleucel

 

ESMO Abstracts

ADAURA trial results at ESMO

ADAURA is a randomized, double-blinded, global, placebo-controlled phase III trial in the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm NSCLC resulting in the complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.

Read More: https://www.delveinsight.com/esmo-conference-2020/article/ADAURA-trial-results-presented-at-esmo-2020

 

Renal Cell Carcinoma Highlights- ESMO 2020

The much-awaited late-breaking results of Phase III Checkmate 9ER came out with outstanding outcomes in metastatic 1st line RCC; it evaluated the combination of Cabozantinib/Nivolumab vs. Sunitinib. These impressive results in 651 patients declared that the median PFS has been doubled when compared to Sunitinib, which is 16.6 vs. 8.3m, respectively. The result also evaluated the OS (40% decrease risk of death) & ORR (55.7 vs. 27.1%), with manageable toxicity, efficacy, and tolerability profile with a low rate of treatment-related discontinuations. It was great to hear that the study met both its primary PFS and secondary OS/ORR, demonstrating the superiority of first-line Cabozantinib/Nivolumab vs Sunitinib across key baseline characteristics, including IMDC risk status, tumor PD-L1 expression, and bone metastases.

Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-9er-renal-cell-carcinoma-highlights-esmo-2020

 

KEYNOTE 048 Results at ESMO 2020

Abstract No : Abstract #915MO

Indication : Head & Neck Cancer

Intervention : Pembrolizumab + Chemotherapy

Company : Merck & Co.

Technology : PD-1 inhibitor + Chemo

Long-term follow-up confirmed the statistically significant improvement in OS established at the protocol-specified interim and final analyses for pembro vs E in pts with PD-L1 CPS ≥20 and CPS ≥1 and for pembro+C vs E in pts with PD-L1 CPS ≥20 and CPS ≥1, and total pop. Safety was favorable for pembro vs E and comparable for pembro+C vs E

Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-048-NCT02358031-esmo-2020

 

KEYNOTE-177 approves pembrolizumab as SoC and an obvious choice for 1L patients MSI-H/dMMR mCRC

Abstract No : Abstract #396O

Indication : Colorectal Cancer

Intervention : Pembrolizumab

Company : Merck & Co.

Technology : Immune Checkpoint Inhibitor (ICI)

Pembro monotherapy demonstrated clinically meaningful improvements in HRQoL vs SOC chemotherapy in pts with previously untreated MSI-H/dMMR mCRC.

Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-177-colorectal-cancer

 

 

Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t...
Read more

Cervical Intraepithelial Neoplasia Market and Epidemiology 2032 by DelveInsight

DelveInsight's " Cervical Intraepithelial Neoplasia Market Insights, Epidemiology, and Market Forecast-2032 " report delivers an in-depth understanding of Cervical Intraepithelial Neoplasia, historical and forecasted epidemiology as well as the Cervical Intraepithelial Neoplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Cervical Intraepithelial Neoplasia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cervical Intraepithelial Neoplasia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Cervical Intraepithelial Neoplasia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cervical Intraepithelial Neoplasia market. Request for a Free Sample Report: Cervic...
Read more

The Need And The Importance Of The Healthcare Reports for the Pharma Companies

Image
It is very important for the hospitals and the other medical institutions to preserve and keep the healthcare reports of all the patients very safe and secure. All the medical records are being kept by almost all of these institutes. As a matter of fact, the healthcare reports are very important for comprehending the medical history of the patient. If he or she suffers from the same ailment once more the previous reports will be absolutely indispensible while treating him or her. Nowadays, with the advancement of technology the manual records are slowly and gradually getting digitalized. It is easier to store and preserve the digital records than the manual and the physical ones.  Choosing The Best And The Most Professional Services For Healthcare Reports: • Rising Pharma Market for You Now In the market there are a host of companies that preserves the healthcare reports of the various patients. All of it is now being done in the digital format due to the adv...
Read more